GRAIL, Inc. (GRAL) · Nov 4, 2026 · Earnings

GRAIL earnings miss as Galleri revenue trails expectations despite FDA boost

Miss — Revenue $37.5M vs ~$44.2M consensus

GRAIL’s Q3 earnings show strong Galleri test growth, but revenue missed consensus and margins deteriorated ahead of a pivotal FDA decision.

GRAIL is commercializing Galleri as a multi-cancer screening test while pursuing FDA approval and broader reimbursement; its regulatory submission is the bridge from early commercial rollout to potential population-scale adoption.

The quarter missed the market’s top-line bar. Published Q3 consensus was approximately $44.2 million of revenue and a $2.45 per-share loss; GRAIL delivered $37.5 million of revenue but a $2.21 per-share loss. The EPS beat is real, but it does not offset a roughly 15% revenue shortfall, making this a revenue-led earnings miss rather than a clean beat. Galleri test revenue grew 14% to $37.3 million, while total revenue grew only 4% because development-services revenue fell sharply. (Financial Highlights)

Q3 2026Q3 2025Consensus
Total revenue (Income Statement)$37.5M (+4%)$36.2M$44.2M
Net loss per share (Income Statement)$(2.21)$(2.46)$(2.45)
Adjusted gross margin (Non-GAAP reconciliation)42%55%
Adjusted EBITDA (Non-GAAP reconciliation)$(92.6)M$(71.7)M

Underlying demand is growing, but monetization and economics are not keeping pace. Galleri test volume rose approximately 24% to more than 56,000 tests, yet test revenue increased only 14%, consistent with the company’s promotional-pricing strategy weighing on revenue per test. 〔0〕 (Business and Financial Results) Adjusted gross margin fell to 42% from 55%, adjusted EBITDA worsened to $92.6 million of losses from $71.7 million, and the GAAP gross loss widened to $18.1 million. (Business and Financial Results) The company is selling more tests, but this quarter does not show operating leverage yet.

The FDA milestone advances the long-term story, but it was already known before earnings. The favorable advisory-panel vote occurred in September, so this filing mainly confirms the next catalyst rather than delivering a fresh regulatory surprise. GRAIL says it anticipates an FDA decision by early Q1 2027. 〔1〕 (Business Highlights) That keeps the regulatory path constructive, but it does not repair the immediate gap between test-volume growth and revenue growth.

Bottom line: GRAIL is gaining commercial traction and remains on an important FDA path, but Q3 showed weaker monetization and worsening margins than the market expected. The business is advancing strategically while execution in the quarter fell short.

What to watch next

FDA decision on Galleri expected by early Q1 2027

Original filing on SEC EDGAR

GRAIL earnings miss as Galleri revenue trails expectations despite FDA boost | GRAL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.